海藻酸钠微球在中晚期原发性肝癌TACE治疗中的应用

Application of KMG to treatment of intermediate and advanced stage primary hepatic carcinoma by TACE

目的探讨海藻酸钠微球(KMG)应用于中晚期原发性肝癌肝动脉化疗栓塞治疗中的疗效及安全性。方法 60例中晚期原发性肝癌患者随机分成KMG组和对照组,KMG组采用KMG进行肝动脉栓塞治疗,对照组采用超氧碘化油进行肝动脉栓塞治疗,比较两组治疗前后瘤体大小、AFP水平、生存率和不良反应。结果治疗1个月后,KMG组瘤体大小明显小于对照组,血清AFP值明显低于对照组(均P<0.05);KMG组1年生存率(80.0%)高于对照组生存率(50.0%)(P<0.05);两组不良反应发生情况无显著差异(P>0.05)。结论海藻酸钠微球栓塞治疗中晚期原发性肝癌安全、有效,能延长患者生存期,可作为中晚期原发性肝癌栓塞治疗的新选择。

Objective To discuss the curative effects and safety of application of kelp micro gelation（KMG） in the treatment of intermediate and advanced stage primary hepatic carcinoma by TACE. Methods Sixty patients with intermediate or advanced stage primary hepatic carcinoma were randomly divided into KMG group and control group. KMP group received the hepatic arterial embolization by KMG, while the control gro up received the hepatic arterial embolization with superoxide lipiodol. Comparison was made in the tumor size, AFP levels, survival rates, and adverse reactions between the two groups. Results After one month of treatment, the tumor sizes in KMG group were significantly smaller than those in the control group; the serum AFP values of the former group were significantly lower than those of the control group（P〈 0.05）; the one-year survival rate of KMG group（80.0%） was higher than that of the control group（50.0%）（P〈 0.05）. There was no significant difference in the occurrence of adverse reactions between the two groups（P〉 0.05）. Conclusion The treatment of intermediate and advanced stage primary hepatic carcinoma by KMG is safe and effective and may prolong the life span. It may be used as a new choice for advanced primary liver cancer embolotherapy.